Atomwise

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. Learn more at atomwise.com, or connect on Twitter and LinkedIn.

Atomwise headquartered in United States, North America, operates in the Biotechnology, Artificial Intelligence (AI), Machine Learning, Health Care, Pharmaceutical, Medical sector. The company focuses on Biotechnology and has secured $38.2B in funding across 216 round(s). With a team of 51-100 employees, Atomwise is actively contributing to advancements in Biotechnology. Their latest funding round, Pre Seed Round - Atomwise, raised $120.0K. Discover more about their projects, partnerships, and impact on our platform.